New hope for melanoma patients
NEWS BRIEFS
New hope for melanoma patients
A new treatment with the gp100 peptide vaccine followed by IV doses of interleukin-2 is showing promise on treating patients with melanoma. Each year, 38,000 people are diagnosed with melanoma — 7,000 die.
The new treatment is being offered at 18 centers around the country participating in the study developed at the National Cancer Institute. The treatment works by generating more activity from the body’s immune system, thus killing the cancer. A protein in the peptide vaccine tricks the body’s immune system into becoming more active to fight the melanoma. The IV treatment with interleukin-2 further increases the body’s immune cell activity.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.